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Management and Implications for Nursing Care
Type 1 Hepatorenal Syndrome
Ernest H. Evans, BSN, RN, CCRN
Introduction
Type 1 hepatorenal syndrome is 
kidney failure that occurs in advanced 
cirrhosis (Fagundes & Ginès, 2012).  It is 
characterized by a, “significant reduction 
in creatinine clearance within 1-2 weeks 
of presentation” (Bacon, 2015). Patients 
that develop this condition have a 
median survival rate of one month 
(Dameron, 2011).  Vasodilation leads to 
decreased perfusion to the kidneys and 
thus kidney injury (Boyer et al., 2011).  
Liver transplantation is the best 
treatment for hepatorenal syndrome 
(Fagundes & Ginès, 2012). Common 
causes of cirrhosis are hepatitis C 
infection, alcohol consumption, and fatty 
liver disease (Warner, Cuthbert, Bhore, 
& Rockey, 2011).  Regardless of the 
cause of cirrhosis, the progression of 
hepatorenal syndrome once identified is 
extremely quick and deadly.
According to the National Institute of 
Diabetes and Digestive and Kidney 
Diseases (2016), cirrhosis is the twelfth 
leading cause of death in the United 
States and accounted for 36,427 deaths 
in 2013.  In 2004, the direct costs 
associated with cirrhosis in the United 
States were $2.5 billion and the indirect 
costs were estimated to be $10.6 billion 
(Neff, Duncan, & Schiff, 2011).  One 
estimate places the prevalence of 
cirrhosis in the United States at 0.27% of 
the population or 644,323 people 
(Scaglione et al., 2015).  Type 2 
hepatorenal syndrome differs from type 
1 in that is has a slower onset and is less 
severe as well as less deadly.  Type 1 
hepatorenal syndrome is an acute 
condition that develops in a short period 
of time (within two weeks).  It is 
important that diagnosis is timely 
because this condition signals likely 
fatality in about 30 days (Dameron, 
2011).  Scaglione et al. (2015) concludes 
that many cases of cirrhosis may be 
undiagnosed and, “more than half are 
potentially preventable by controlling 
diabetes, alcohol abuse, and viral 
hepatitis” (p. 690).  Perhaps, the 
dissemination of information to the 
general public about the safety concerns 
related to obesity, hepatitis 
transmission, and alcohol use can 
increase self-preventative interventions 
and decrease deaths related to liver 
disease.
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Though type 1 hepatorenal
syndrome is an acute process, it is 
preceded by the chronic development of 
liver cirrhosis.  Widespread fibrosis of 
the liver and the development of 
abnormal liver nodules is typically 
caused by one of three mechanisms:
• Alcoholic liver disease
• Hepatitis
• Nonalcoholic fatty liver disease
Any of these conditions can lead to 
cirrhosis (Perri, 2013).
The effects of advanced liver disease 
are many, often comorbid, and 
interrelated.  They include:
• Portal hypertension
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The best evidence suggests that the 
kidney dysfunction associated with type 
1 hepatorenal syndrome is secondary to 
reduced circulatory function (Fagundes & 
Ginès, 2012).  Cirrhosis is fibrotic 
scarring of the liver cells usually caused 
by chronic exposure to harmful agents.  
This sustained scarring causes reduction 
in vascular structure leading to a 
condition called portal hypertension 
(Møller & Bendtsen, 2015).  The two 
factors that lead to the development of 
portal hypertension are increased 
resistance to blood flow through the liver 
and splanchnic vasodilation.  One of the 
most visibly obvious symptoms 
associated with portal hypertension is 
ascites, accumulation of fluid within the 
peritoneal cavity.  Ascites is often present 
in those that develop hepatorenal
syndrome (Bacon, 2015).  Often, the 
acute onset of type 1 hepatorenal
syndrome is preceded by a severe 
infection known as spontaneous 
Pathophysiology
bacterial peritonitis. One third of those 
affected by spontaneous bacterial 
peritonitis will develop hepatorenal
syndrome. Severe liver disease is the 
underlying chronic condition that leaves 
those affected with reduced immunity 
and increased susceptibility.  With the 
presence of ascites, the peritoneal cavity 
proves to be a wonderful environment 
for bacterial proliferation (Møller & 
Bendtsen, 2015).   Hepatorenal
syndrome is characterized by increased 
vascular resistance in the renal 
circulation and reduced vascular 
resistance in the peripheral circulation 
(Bacon, 2015).  This activates the renin-
angiotensin-aldosterone system with 
even further enhancement of renal 
vasoconstriction and a severe imbalance 
of systemic and renal vasodilation 
(Dameron, 2011). There is no direct 
problem with the kidneys but rather they 
are being deprived of the necessary 
perfusion to maintain adequate function.
• Exposure to agents such as hepatitis viruses and 
alcohol
• Liver scarring, loss of function, and loss of normal 
vascularity
• Increased production of nitric oxide and other 
vasodilating substances
• Central hypovolemia, caused by “third-spacing”
• Widespread splanchnic vasodilation and portal 
hypertension leading to ascites
• Spontaneous bacterial peritonitis
• Renal hypertension, peripheral hypotension, and 
reduced kidney perfusion
• Type 1 hepatorenal syndrome
Figure 1: Compensated versus decompensated cirrhosis leading to renal 
failure (Fagundes & Ginès, 2012)
Cirrhosis
• Esophageal varices
• Hypersplenism
• Spontaneous bacterial 
peritonitis
• Hepatorenal syndrome
• Hepatic encephalopathy
• Coagulopathy
• Ascites
(Bacon, 2015)
According to Perri (2013), 
ascites is the main complication of 
cirrhosis and the mean time 
period to its development in liver 
disease is ten years.  Mortality 
after diagnosis is estimated at fifty 
percent in two years.  Ascites is 
almost always present in those 
that develop hepatorenal
syndrome (Bacon, 2015).
Treatment of type 1 hepatorenal
syndrome can include:
• Inpatient critical care setting 
management
• The administration of 
vasoconstrictors
• The administration of albumin
• Renal replacement therapy
• Transjugular intrahepatic 
portosystemic shunt placement
• Liver transplant
The best option for patients with 
type 1 hepatorenal syndrome is a 
liver transplant.  If performed early 
enough, kidney function will likely be 
preserved (Fagundes & Ginès, 2012).
The significance of type 1 
hepatorenal syndrome should not be 
underestimated:
• Cirrhosis is the twelfth leading 
cause of death in the United 
States (Guirguis et al., 2015)
• The costs associated with 
cirrhosis are in the billions 
annually (Neff, Duncan, & Schiff, 
2011)
Conclusion
Primary prevention of type 1 
hepatorenal syndrome is directly 
related to the prevention of liver 
disease.  This includes vaccination for 
hepatitis B, safe sex practices, 
moderation or abstinence of alcohol 
intake, and diet and exercise to 
control weight.  Secondary prevention 
would include reduction of alcohol 
intake and weight loss.  Some tertiary 
preventative options include the use 
of albumin administration for those 
with spontaneous bacterial peritonitis 
and the prophylactic administration 
of antibiotics in patients at high risk 
(Fagundes & Ginès, 2012).
Process
• Those who do not receive 
advanced treatment will likely die 
in about thirty days (Dameron, 
2011)
• Most risk factors for developing 
this condition are preventable 
(Scaglione et al., 2015)
Figure 2: Transjugular
intrahepatic portosystemic shunt 
(Dameron, 2011)
Hepatorenal syndrome type 1 is a 
severe and deadly manifestation of end 
stage liver disease.  It is a direct 
consequence of the vasoactive effects 
of advanced cirrhosis such as portal 
hypertension, splanchnic vasodilation, 
and the imbalance of peripheral and 
renal bloodflow.  Additionally, ascites 
with spontaneous bacterial peritonitis 
appears to be closely linked with the 
development of hepatorenal syndrome
(Møller & Bendtsen, 2015).  Though it 
is in itself an acute syndrome, the 
factors that precipitate the 
development of the condition are 
mostly preventable.  Through 
educating patients about the 
importance of moderation in alcohol 
intake, receiving vaccinations, 
maintaining a healthy weight, among 
other self care practices, a reduction in 
preventable mortality can be achieved.  
There are also treatments to slow the 
progression and relieve the symptoms 
of those affected by cirrhosis.
